Abstract
A survey of 347 patients on treatment with hydroxychloroquine showed that a mild pigmentary maculopathy was present in 29 per cent of cases if a cumulative dose of more than 800 g of the drug had been ingested. Most of the affected patients showed no deterioration in visual function. The significance of these findings is discussed with particular regard to the screening of patients on hydroxychloroquine therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
